Skip to content
MARKETS / NASDAQ / COLL
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Collegium Pharmaceutical, Inc. COLL

13 fiscal years on record · USD · FY2025 reported · SEC filings only
$780.6M
▲ 23.6% YoY
$62.9M
▼ 9.1% YoY
$327.6M
▲ 61.1% YoY
In brief

What this company does

It has developed, licensed and acquired this portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. As of December 31, 2025, it had a total of 423 full-time employees. It commercializes its products in the United States through two dedicated field sales forces, one focused on its pain portfolio and the other on ADHD, and its pain sales force consists of approximately 105 sales representatives and managers who call on approximately 10,000 health care professionals writing approximately 67% of the branded extended-release opioid prescriptions in the United States. Its ADHD sales force consists of approximately 200 sales representatives and managers who call on approximately 21,000 health care professionals writing approximately 60% of the pediatric and adolescent extended-release stimulant prescriptions in the United States. It is headquartered in Stoughton, Massachusetts. Collegium Pharmaceutical, Inc.'s predecessor was incorporated in Delaware in April 2002 under the name Collegium Pharmaceuticals, Inc., changed its name to Collegium Pharmaceutical, Inc. in October 2003, and reincorporated in the Commonwealth of Virginia in July 2014.

Written from the business description in COLLEGIUM PHARMACEUTICAL, INC's annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth
USD 780.6M
Revenue, FY2025 · full 13-year series below
Revenue $M Net income $M
FY2025 · Revenue 780.6 · Net income 62.9
400M-40M-80M2013201520172019202120232025
Compound annual growth
+18.9%
+20.3%
+18.6%
+17.9%
+109.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +20.3% a year over five years — but profit grew slower: net income at +18.6%, earnings per share at +17.9%.

The share count fell from 0.03B to 0.03B — the buyback concentrates the same profit into fewer slices.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
8 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 23.0% · Net 8.1%
-2000%-4000%2013201520172019202120232025
ROE
FY2025 · ROE 23.7%
10%20%30%-50%2013201520172019202120232025

Each USD of equity produced 24 cents of profit this year.

Cash & shareholders
USD 20.8M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 327.6
200M-40M2013201520172019202120232025
Net buybacks $M Dividends $M
FY2025 · Dividends — · Net buybacks 20.8
25.0M50.0M20212022202320242025

USD 20.8M in buybacks — 33% of the year's profit went back to shareholders.

Total assetsUSD 1.7B
EquityUSD 301.7M
CashUSD 231.3M
Current ratio1.57×

Equity funds 18% of total assets.

The 13-year record
13 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013
Revenue $B0.80.60.60.50.30.30.30.30.00.0···
Operating income $B0.20.20.20.00.00.1−0.0−0.0−0.1−0.1−0.0−0.0−0.0
EBITDA $B0.20.20.20.00.00.1−0.0−0.0−0.1−0.1−0.0−0.0−0.0
Income tax $B0.00.00.0−0.0−0.10.00.0······
Net income $B0.10.10.0−0.00.10.0−0.0−0.0−0.1−0.1−0.0−0.0−0.0
Free cash flow $B0.30.20.30.10.10.10.00.2−0.1−0.1−0.0−0.0−0.0
EPS, diluted $1.731.861.29−0.741.860.76−0.68−1.19−2.47−3.88−1.48−22.72−4.06
Dividend / sh $·············
Payout %·············
ROE %23.732.624.7−12.636.819.6−25.4−40.0−62.7−85.6···
Shares out B0.030.030.030.030.030.030.030.030.030.030.020.000.00

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 3 failures in 58 reconciliationsAUDITED

Reconciled in 10 of 19 fiscal years. 35 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente3 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inVirginia
Fiscal year endsDecember 31
Data on record since2013

Share this section

Download image